Log in
NASDAQ:QTRX

Quanterix Stock Forecast, Price & News

$33.90
+0.74 (+2.23 %)
(As of 09/19/2020 12:07 AM ET)
Add
Compare
Today's Range
$32.90
Now: $33.90▼
$34.06
50-Day Range
$30.73
MA: $33.74▼
$36.77
52-Week Range
$10.90
Now: $33.90▼
$37.77
Volume591,500 shs
Average Volume194,607 shs
Market Capitalization$964.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.78
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.
Read More
Quanterix logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.27 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QTRX
Previous Symbol
CUSIPN/A
CIK1503274
Webwww.quanterix.com
Phone617-301-9400

Debt

Debt-to-Equity Ratio0.07
Current Ratio6.05
Quick Ratio5.32

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$56.73 million
Price / Sales16.99
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.59 per share
Price / Book7.39

Profitability

EPS (Most Recent Fiscal Year)($1.63)
Net Income$-40,800,000.00
Net Margins-73.39%
Return on Equity-35.42%
Return on Assets-25.83%

Miscellaneous

Employees177
Outstanding Shares28,440,000
Market Cap$964.12 million
Next Earnings Date11/13/2020 (Estimated)
OptionableNot Optionable
$33.90
+0.74 (+2.23 %)
(As of 09/19/2020 12:07 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Quanterix (NASDAQ:QTRX) Frequently Asked Questions

How has Quanterix's stock been impacted by COVID-19 (Coronavirus)?

Quanterix's stock was trading at $18.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, QTRX stock has increased by 83.1% and is now trading at $33.90.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Quanterix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Quanterix.

When is Quanterix's next earnings date?

Quanterix is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Quanterix.

What price target have analysts set for QTRX?

3 analysts have issued 1-year target prices for Quanterix's shares. Their forecasts range from $36.00 to $40.00. On average, they anticipate Quanterix's stock price to reach $37.67 in the next year. This suggests a possible upside of 11.1% from the stock's current price.
View analysts' price targets for Quanterix.

Are investors shorting Quanterix?

Quanterix saw a decline in short interest in August. As of August 14th, there was short interest totaling 865,100 shares, a decline of 17.6% from the July 30th total of 1,050,000 shares. Based on an average daily volume of 247,800 shares, the days-to-cover ratio is currently 3.5 days. Approximately 4.0% of the shares of the stock are sold short.
View Quanterix's Short Interest.

Who are some of Quanterix's key competitors?

Some companies that are related to Quanterix include Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Harvard Bioscience (HBIO), BioNano Genomics (BNGO), Eyepoint Pharmaceuticals (EYPT), Precipio (PRPO), HTG Molecular Diagnostics (HTGM), BioForce Nanosciences (BFNH), Astrotech (ASTC), Scientific Industries (SCND), Pressure Biosciences (PBIO) and Arrayit (ARYC).
View all competitors.

What other stocks do shareholders of Quanterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Akoustis Technologies (AKTS), Crispr Therapeutics (CRSP), Walt Disney (DIS), Editas Medicine (EDIT), Novavax (NVAX), Allena Pharmaceuticals (ALNA), Cisco Systems (CSCO), Illumina (ILMN), Intellia Therapeutics (NTLA) and Spero Therapeutics (SPRO).

Who are Quanterix's key executives?

Quanterix's management team includes the following people:
  • Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 58)
  • Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 66)
  • Dr. David C. Duffy Ph.D., Sr. VP of R&D and CTO (Age 48)
  • Mr. Amol Chaubal, Chief Financial Officer (Age 43)
  • Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 60)

When did Quanterix IPO?

(QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

What is Quanterix's stock symbol?

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Who are Quanterix's major shareholders?

Quanterix's stock is owned by a variety of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (9.61%), Macquarie Group Ltd. (4.94%), Vanguard Group Inc. (3.46%), Frontier Capital Management Co. LLC (2.96%), Bellevue Group AG (1.68%) and Ashford Capital Management Inc. (1.64%). Company insiders that own Quanterix stock include Amol Chaubal, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, Ernest Orticerio, John J Fry, John M Connolly, Joseph Driscoll, Marijn E Dekkers, Mark T Roskey and Martin D Madaus.
View institutional ownership trends for Quanterix.

Which major investors are selling Quanterix stock?

QTRX stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Portolan Capital Management LLC, Ashford Capital Management Inc., FMR LLC, Silvercrest Asset Management Group LLC, Platinum Investment Management Ltd., First Republic Investment Management Inc., and WINTON GROUP Ltd. Company insiders that have sold Quanterix company stock in the last year include Amol Chaubal, David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, Mark T Roskey, and Martin D Madaus.
View insider buying and selling activity for Quanterix.

Which major investors are buying Quanterix stock?

QTRX stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Moody Aldrich Partners LLC, Vanguard Group Inc., Cadence Capital Management LLC, Nuveen Asset Management LLC, Marshall Wace LLP, Marathon Capital Management, and Cannell Peter B & Co. Inc.. Company insiders that have bought Quanterix stock in the last two years include David R Walt, and John M Connolly.
View insider buying and selling activity for Quanterix.

How do I buy shares of Quanterix?

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quanterix's stock price today?

One share of QTRX stock can currently be purchased for approximately $33.90.

How big of a company is Quanterix?

Quanterix has a market capitalization of $964.12 million and generates $56.73 million in revenue each year. The company earns $-40,800,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Quanterix employs 177 workers across the globe.

What is Quanterix's official website?

The official website for Quanterix is www.quanterix.com.

How can I contact Quanterix?

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.